UNFO Med has launched a corrective foot brace designed to treat various foot conditions in newborns, including metatarsus adductus (MTA).

The new device offers a non-invasive alternative to traditional casting and surgical interventions, potentially transforming the standard of care for infants with such conditions.

MTA is a congenital foot condition affecting approximately 7% of newborns, with a higher incidence of 12% in the siblings of affected children.

The UNFO system, developed by UNFO Med founder and R&D director Dr Izak Daizade, is a short foot orthotic device that is worn below the ankle.

It is designed to correct the three-dimensional anatomic deformities and misalignments in infants' foot structures.

Daizade has successfully treated more than 15,000 patients with the UNFO brace, achieving a 95% success rate.

He noted that the UNFO system is the result of seven years of research and represents a first in paediatric orthopaedics.

It has a discreet, sandal-like design that ensures proper correction while delivering gentle and comfortable care for the newborns.

Daizade said: “As a paediatric orthopaedic specialist, my goal has always been to provide the best possible care for newborns facing challenges such as MTA.

“UNFO's corrective foot brace represents a significant advancement in our approach to pediatric orthopaedics. This non-invasive solution not only transforms the treatment of newborns born with MTA but also signifies a new era of proactive and compassionate care.

“I am excited about the positive impact this innovation will have on the lives of infants and their families across the US.”

The company is offering the UNFO brace for orthopaedic specialists and medical practitioners in the US, including the Mount Sinai Hospital in Baltimore and select healthcare facilities across the nation.